The Global Prostate Cancer Market is expected to grow with a CAGR of approximately 10.5% during the forecast period from 2017-2027. prostate cancer is a disease of the prostate gland. These glands are responsible for the production and secretion of prostate fluid as a component of semen in addition to that it also acts as a regulator of urine control in men.
International Prostate Cancer Market Business Overview:
As per a survey conducted by the American Cancer Society, about 1 in 7 men are estimated to be diagnosed with prostate cancer during their lifetime. Moreover, according to a UK based government institute namely Cancer Research Organization estimated that nearly 46,690 new cases of prostate cancer were diagnosed in 2014 with a death toll of 11,287 patients. Furthermore, there are various initiatives undertaken by key players to collaborate with government organization to spread awareness regarding the clinical symptoms of prostate cancer. Moreover, the promotion of diagnostic & screening tests for early detection such as Digital Rectal Exam (DRE), and Prostate-Specific Antigen (PSA). In addition, major players including Dendreon Corporation, Sanofi, AstraZeneca Plc, Johnson & Johnson Inc., and Astellas Pharms, Inc., are aiming to develop safe and effective therapeutic products to treat tumor.
Besides, blockbuster drugs such as Zytiga, Taxotere, Xtandi, Eligard, Xofigo, and Provenge, holding a robust position in the global prostate cancer market. Johnson & Johnson’s brand Zytiga is considered as a gold standard for the treatment of prostate cancer. Rise in the funding in both private and public sector for the drug development, technological advancements in finding new techniques to fight prostate cancer, lifestyle changes, are few factors driving the growth of the market. Side effects of surgery such as urinary impotence & incontinence and surgical risks such as blood clots, stroke, and heart attack are certain constraints encountered by the global prostate cancer market.
Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/1580 .
Prostate Cancer Market Top Key Players Overview:
OncoGenex Pharmaceuticals Inc., Bayer Pharma AG (Germany), Progenics Pharmaceuticals, Inc. (US), TOLMAR Inc. (US), OncBioMune Pharmaceuticals Inc. (US), Endo Pharmaceuticals Inc. (US), Tokai Pharmaceuticals Inc. (US), Active Biotech (US), ADC Therapeutics (US), Advantagene (US), Advaxis Pharmaceuticals (US), ANI Pharmaceuticals (US), ArQule (US), Athenex Pharmaceuticals (US), Bavarian Nordic (US), BHR Pharma (US), Boehringer Ingelheim (Germany), Cleveland BioLabs (US), Dextech Medical (US), Eisai (US), Endo Pharmaceuticals (US), Ferring Pharmaceutical (US), GTx (US), Innocrin Pharmaceutical (US), Inspyr Therapeutics (US), Io Therapeutics (US), Lidds AB (US), Merck Group (US), Myovant Sciences (US), Northwest Biotherapeutics (US), Novartis AG (Switerzland), Nymox Pharmaceuticals (US), OncoGenex (US), Oncolytics Biotech (US), Orion (US), CureVac (US), Pharmamar (US), Camurus (US), Foresee Pharmaceuticals (US), Progenics Pharmaceuticals (US), Sotio (US), Spectrum Pharmaceuticals (US), Synta (US), Takeda Pharmaceuticals (Japan), Teva Pharmaceutical (Israel), Tokai Pharmaceuticals (US), AbbVie (US), Astellas Pharma (Japan), AstraZeneca (US), Johnson & Johnson (US), Sanofi (France), Ipsen (US), Valeant Pharmaceuticals (US), Dendreon Corporation (US), and others are some of the prominent players at the forefront of competition in the global prostate cancer market and are profiled in MRFR Analysis.
March, 2018 Astellas pharma received FDA approval for Xtandi tablets, a treatment for castration-resistant prostate cancer, in Japan
Jan, 2015 Janssen Pharmaceutical Companies r received FDA approval for Zytiga (abiraterone acetate) for the treatment of prostate cancer
Global Prostate Cancer Market – Regional Analysis:
The global prostate cancer market is segmented into five major regions including Americas, Europe, Asia Pacific, and Middle East and Africa region.
Americas dominated the global prostate cancer market in terms of revenue share owing to the increasing R&D in the region and presence of big outsourcing firms. In the U.S., it is the most common cancer in men, but it is also treatable if found in the early stages. Prostate Cancer Foundation of Canada supports research, cure, and prevention of prostate cancer via online portal. According to the American Cancer Society in 2017 expected that about 161,360 new cases of prostate cancer will be diagnoses, and that around 26,730 fatalities will occur because of it.
The European market is the second largest market for prostate cancer plays an important role to minimize the cost of clinical trials. Furthermore, Asia Pacific region has emerged as the fastest growing market for prostate cancer.
The Middle-East and Africa prostate cancer market has been evaluated as moderately growing market and it is expected that the market will continue to grow at same pace in the near future.
Glad to Know If there are Any Queries Related to Prostate Cancer Market Report @ https://www.marketresearchfuture.com/enquiry/1580 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312